GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
A Study to Evaluate Immune Response and Safety of Two Doses of GSK Biologicals' HRV Liquid Vaccine in Healthy Infants.
Phase 2
Completed
- Conditions
- Rotavirus VaccinesInfections, Rotavirus
- Interventions
- Biological: PlaceboBiological: Rotarix™
- First Posted Date
- 2007-02-07
- Last Posted Date
- 2020-01-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 375
- Registration Number
- NCT00432380
- Locations
- 🇵🇭
GSK Investigational Site, Muntinlupa, Philippines
A Study of the Drug Casopitant for the Prevention of Nausea Caused By Cisplatin-Based Highly Emetogenic Chemotherapy
Phase 3
Completed
- Conditions
- Nausea and Vomiting, Chemotherapy-Induced
- First Posted Date
- 2007-02-05
- Last Posted Date
- 2017-08-22
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 810
- Registration Number
- NCT00431236
- Locations
- 🇺🇦
GSK Investigational Site, Uzhgorod, Ukraine
Safety & Immunogenicity of an Alternative Immunization Schedule of GSK Bio's Pandemic Influenza Vaccine (GSK1119711A)
Phase 2
Completed
- Conditions
- InfluenzaInfluenza Vaccines
- Interventions
- Biological: Pandemic influenza vaccine (GSK1119711A)-formulation 1Biological: Pandemic influenza vaccine (GSK1119711A)-formulation 2
- First Posted Date
- 2007-02-02
- Last Posted Date
- 2019-10-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 512
- Registration Number
- NCT00430521
- Locations
- 🇩🇪
GSK Investigational Site, Hamburg, Germany
Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer
Phase 2
Completed
- Conditions
- Neoplasms, Uterine CervixMetastatic Cervical Cancer
- Interventions
- First Posted Date
- 2007-02-02
- Last Posted Date
- 2015-05-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 228
- Registration Number
- NCT00430781
- Locations
- 🇹🇭
GSK Investigational Site, Khon Kaen, Thailand
A Study To Investigate The Metabolism Of GW876008 In Smokers Compared To Non-Smokers.
Phase 1
Completed
- Conditions
- Healthy Subjects
- First Posted Date
- 2007-02-01
- Last Posted Date
- 2009-05-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 26
- Registration Number
- NCT00429728
- Locations
- 🇺🇸
GSK Investigational Site, Willingboro, New Jersey, United States
Trial With Allergic Rhinitis Patients Taking GSK256066 Versus Placebo In A Pollen Challenge Chamber
Phase 2
Completed
- Conditions
- Rhinitis, Allergic, SeasonalSeasonal Allergic Rhinitis
- First Posted Date
- 2007-02-01
- Last Posted Date
- 2012-06-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 45
- Registration Number
- NCT00430157
- Locations
- 🇦🇹
GSK Investigational Site, Vienna, Austria
Assess Efficacy, Immune Response & Safety of 2 Doses of Oral Live Attenuated HRV Vaccine at Different Viral Concentrations in Healthy Infants
Phase 2
Completed
- Conditions
- Hepatitis B
- First Posted Date
- 2007-01-31
- Last Posted Date
- 2016-09-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 2464
- Registration Number
- NCT00429481
Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast Cancer
Phase 2
Completed
- Conditions
- Neoplasms, Breast
- Interventions
- Drug: lapatinibBiological: trastuzumabDrug: paclitaxelDrug: epidoxorubicinDrug: fluorouracilDrug: cyclophosphamide
- First Posted Date
- 2007-01-31
- Last Posted Date
- 2016-03-22
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 121
- Registration Number
- NCT00429299
- Locations
- 🇵🇱
GSK Investigational Site, Warszawa, Poland
Study in Children to Evaluate Non-Inferiority and Persistence up to 5 Years of GSK Bio Meningococcal Vaccine 134612
Phase 2
Completed
- Conditions
- Infections, Meningococcal
- Interventions
- Biological: Mencevax™ ACWYBiological: GSK Biolgicals' meningococcal vaccine 134612 (Nimenrix)Biological: Meningitec™
- First Posted Date
- 2007-01-29
- Last Posted Date
- 2018-06-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 613
- Registration Number
- NCT00427908
- Locations
- 🇫🇮
GSK Investigational Site, Vantaa, Finland
A Two-Part Study to Determine: Best Medication Formulation and Food Effect
Phase 1
Completed
- Conditions
- Overactive Bladder
- First Posted Date
- 2007-01-29
- Last Posted Date
- 2008-10-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 18
- Registration Number
- NCT00427596
- Locations
- 🇺🇸
GSK Investigational Site, Buffalo, New York, United States
© Copyright 2025. All Rights Reserved by MedPath